Current Disease-Modifying Therapeutic Strategies in Multiple Sclerosis

Research output: Contribution to journalArticle

Abstract

Therapeutic options continue to expand for patients with multiple sclerosis (MS). MS is a potentially disabling, lifelong disease with a wide spectrum of clinical manifestations and tremendous interindividual variability of disease course. This chapter summarizes and integrates the evidence supporting the use of various agents such as natalizumab and glatiramer acetate, as well as other available but unapproved treatments, by outlining contemporary treatment strategies. It also focuses on early-course treatment decisions for established MS; the clinically isolated syndromes (CIS), management of aggressive MS, and future approaches are detailed. The therapies approved for relapsing forms of MS are discussed. The features of the available disease-modifying treatments (DMTs) are summarized and the pivotal trial data and clinically relevant interpretation of relapses and disability using the number needed-to-treat (NNT) are tabulated. Three Interferon-beta (IFNB) preparations are approved for relapsing MS: IFNbeta-1a, rebif, and IFN-beta-1b. Treatment intolerance or declaration of treatment failure should lead to switching therapy. Every MS patient should be encour­aged to consider participation in a clinical trial, especially those patients who have breakthrough disease despite therapy, rapidly worsening MS, or progressive forms of the disease.

Original languageEnglish (US)
Pages (from-to)284-303
Number of pages20
JournalBlue Books of Neurology
Volume35
Issue numberC
DOIs
StatePublished - Jan 1 2010

Fingerprint

Multiple Sclerosis
Therapeutics
Numbers Needed To Treat
Interferon-beta
Treatment Failure
Clinical Trials
Recurrence

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Current Disease-Modifying Therapeutic Strategies in Multiple Sclerosis. / Jacob, Anu; Wingerchuk, Dean Marko.

In: Blue Books of Neurology, Vol. 35, No. C, 01.01.2010, p. 284-303.

Research output: Contribution to journalArticle

@article{81b341d346ab4a019720e9e24ba88203,
title = "Current Disease-Modifying Therapeutic Strategies in Multiple Sclerosis",
abstract = "Therapeutic options continue to expand for patients with multiple sclerosis (MS). MS is a potentially disabling, lifelong disease with a wide spectrum of clinical manifestations and tremendous interindividual variability of disease course. This chapter summarizes and integrates the evidence supporting the use of various agents such as natalizumab and glatiramer acetate, as well as other available but unapproved treatments, by outlining contemporary treatment strategies. It also focuses on early-course treatment decisions for established MS; the clinically isolated syndromes (CIS), management of aggressive MS, and future approaches are detailed. The therapies approved for relapsing forms of MS are discussed. The features of the available disease-modifying treatments (DMTs) are summarized and the pivotal trial data and clinically relevant interpretation of relapses and disability using the number needed-to-treat (NNT) are tabulated. Three Interferon-beta (IFNB) preparations are approved for relapsing MS: IFNbeta-1a, rebif, and IFN-beta-1b. Treatment intolerance or declaration of treatment failure should lead to switching therapy. Every MS patient should be encour­aged to consider participation in a clinical trial, especially those patients who have breakthrough disease despite therapy, rapidly worsening MS, or progressive forms of the disease.",
author = "Anu Jacob and Wingerchuk, {Dean Marko}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/B978-1-4160-6068-0.00015-2",
language = "English (US)",
volume = "35",
pages = "284--303",
journal = "Blue Books of Neurology",
issn = "1877-184X",
publisher = "Elsevier Inc.",
number = "C",

}

TY - JOUR

T1 - Current Disease-Modifying Therapeutic Strategies in Multiple Sclerosis

AU - Jacob, Anu

AU - Wingerchuk, Dean Marko

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Therapeutic options continue to expand for patients with multiple sclerosis (MS). MS is a potentially disabling, lifelong disease with a wide spectrum of clinical manifestations and tremendous interindividual variability of disease course. This chapter summarizes and integrates the evidence supporting the use of various agents such as natalizumab and glatiramer acetate, as well as other available but unapproved treatments, by outlining contemporary treatment strategies. It also focuses on early-course treatment decisions for established MS; the clinically isolated syndromes (CIS), management of aggressive MS, and future approaches are detailed. The therapies approved for relapsing forms of MS are discussed. The features of the available disease-modifying treatments (DMTs) are summarized and the pivotal trial data and clinically relevant interpretation of relapses and disability using the number needed-to-treat (NNT) are tabulated. Three Interferon-beta (IFNB) preparations are approved for relapsing MS: IFNbeta-1a, rebif, and IFN-beta-1b. Treatment intolerance or declaration of treatment failure should lead to switching therapy. Every MS patient should be encour­aged to consider participation in a clinical trial, especially those patients who have breakthrough disease despite therapy, rapidly worsening MS, or progressive forms of the disease.

AB - Therapeutic options continue to expand for patients with multiple sclerosis (MS). MS is a potentially disabling, lifelong disease with a wide spectrum of clinical manifestations and tremendous interindividual variability of disease course. This chapter summarizes and integrates the evidence supporting the use of various agents such as natalizumab and glatiramer acetate, as well as other available but unapproved treatments, by outlining contemporary treatment strategies. It also focuses on early-course treatment decisions for established MS; the clinically isolated syndromes (CIS), management of aggressive MS, and future approaches are detailed. The therapies approved for relapsing forms of MS are discussed. The features of the available disease-modifying treatments (DMTs) are summarized and the pivotal trial data and clinically relevant interpretation of relapses and disability using the number needed-to-treat (NNT) are tabulated. Three Interferon-beta (IFNB) preparations are approved for relapsing MS: IFNbeta-1a, rebif, and IFN-beta-1b. Treatment intolerance or declaration of treatment failure should lead to switching therapy. Every MS patient should be encour­aged to consider participation in a clinical trial, especially those patients who have breakthrough disease despite therapy, rapidly worsening MS, or progressive forms of the disease.

UR - http://www.scopus.com/inward/record.url?scp=85023122474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023122474&partnerID=8YFLogxK

U2 - 10.1016/B978-1-4160-6068-0.00015-2

DO - 10.1016/B978-1-4160-6068-0.00015-2

M3 - Article

AN - SCOPUS:85023122474

VL - 35

SP - 284

EP - 303

JO - Blue Books of Neurology

JF - Blue Books of Neurology

SN - 1877-184X

IS - C

ER -